Exposure | Hazard ratio for deaths (95% CI) | P-value | Hazard ratio for discharge–time adjusted (95% CI) | P-value | Hazard ratio for discharge–time adjusted (95% CI) only survivors (n = 70) | P-value |
---|---|---|---|---|---|---|
Basic parameter | ||||||
Male sex | 1.02 (0.55-1.88) | 0.95 | 1.14 (0.77-1.68) | 0.5 | 1.28 (0.77-2.12) | 0.32 |
Age, years | 1.0073 (0.9889-1.0261)* | 0.43 | 1.0164 (1.0039-1.0291)* | 0.007 | 1.0155 (0.9938-1.033)* | 0.07 |
Nosocomial infection | 2.14 (1.05-4.27) | 0.03 | 0.67 (0.42-1.07) | 0.1 | 0.52 (0.28-0.97) | 0.04 |
Origin of bacteremia | ||||||
Unknown (primary BSI) | 1.07 (0.57-2) | 0.83 | 1.85 (1.24-2.75) | 0.003 | 2.22 (1.32-3.73) | 0.003 |
Secondary BSI | 1.25 (0.67-2.31) | 0.47 | 0.79 (0.53-1.16) | 0.24 | 0.76 (0.46-1.25) | 0.29 |
VC BSI | 0.22 (0.03-1.66) | 0.06 | 0.39 (0.18-0.85) | 0.008 | 0.37 (0.15-0.89) | 0.01 |
Comorbid conditions | ||||||
Immune suppression | 2.31 (0.71-7.55) | 0.12 | 0.54 (0.31-0.94) | 0.04 | 0.5 (0.26-0.96) | 0.04 |
Haematological cancer | 1.23 (0.67-2.28) | 0.5 | 0.61 (0.39-0.93) | 0.02 | 0.5 (0.27-0.91) | 0.02 |
Chemotherapy | 0.83 (0.45-1.56) | 0.58 | 0.62 (0.41-0.94) | 0.02 | 0.6 (0.35-1.03) | 0.06 |
Cardiovascular disease | 0.65 (0.36-1.2) | 0.18 | 0.77 (0.52-1.14) | 0.2 | 0.83 (0.49-1.38) | 0.48 |
Diabetes | 1.43 (0.77-2.65) | 0.25 | 0.78 (0.51-1.19) | 0.25 | 0.55 (0.31-0.99) | 0.04 |
Charlson Comorbidity Score | 0.96 (0.83-1.11)* | 0.66 | 1 (0.92-1.1)* | 0.83 | 1.01 (0.9-1.13)* | 0.77 |
Patients clinical record | ||||||
SAPS II | 1.0375 (1.0184-1.057)* | <0.001 | 0.9961 (0.9828-1.0097)* | 0.58 | 0.974 (0.9557-0.9926)* | 0.005 |
Neutropenia | 1.41 (0.77-2.58) | 0.27 | 0.62 (0.4-0.94)† | 0.02 | 0.43 (0.23-0.79) | 0.004 |
Chemotherapy | 0.83 (0.45-1.56) | 0.58 | 0.62 (0.41-0.94) | 0.02 | 0.6 (0.35-1.03) | 0.06 |
Steroids | 1.82 (0.86-3.84) | 0.1 | 0.46 (0.3-0.7) | <0.001 | 0.3 (0.17-0.54) | <0.001 |
Concomitant infections | 1.22 (0.56-2.71) | 0.59 | 0.27 (0.16-0.44) | <0.001 | 0.23 (0.11-0.46) | <0.001 |
Recent surgery | 0.65 (0.34-1.22) | 0.18 | 0.54 (0.35-0.81) | 0.003 | 0.47 (0.27-0.82) | 0.007 |
AET | 0.81 (0.44-1.5) | 0.52 | 0.89 (0.59-1.34) | 0.6 | 0.9 (0.53-1.51) | 0.7 |
ADT | 0.33 (0.16-0.68) | 0.007 | 0.44 (0.25-0.77) | 0.008 | 0.4 (0.17-0.92) | 0.052 |
Pathogen exposure | ||||||
MBL-PA | 1.83 (0.92-3.64) | 0.1 | 0.75 (0.44-1.27) | 0.27 | 0.49 (0.21-1.17) | 0.08 |
3/4MDR-PA | 1.98 (1.07-3.67) | 0.03 | 0.76 (0.49-1.19) | 0.23 | 0.55 (0.25-1.07) | 0.06 |
MEM-resistant PA | 1.98 (1.08-3.62) | 0.03 | 0.85 (0.55-1.3) | 0.45 | 0.64 (0.33-1.23) | 0.17 |
CAZ-resistant PA | 1.88 (0.99-3.57) | 0.06 | 0.72 (0.45-1.16) | 0.17 | 0.53 (0.25-1.15) | 0.09 |
CIP-resistant PA | 1.27 (0.69-2.34) | 0.43 | 0.93 (0.62-1.39) | 0.73 | 0.78 (0.45-1.34) | 0.38 |
TZP-resistant PA | 1.41 (0.76-2.61) | 0.28 | 0.78 (0.52-1.19) | 0.26 | 0.68 (0.37-1.23) | 0.2 |